“Access to capital increases when there’s an exit”

During a long period of low interest rates, followed by a pandemic, the valuations of Swedish biotech companies rose sharply up until 2021. An unusually high number of IPOs took place, not least among early‑stage companies.

But the past few years have brought a significant backlash, Okee Williams noted when speaking at the Pharma Outsourcing conference on Tuesday.